NASH and Systemic Complications
Nonalcoholic fatty liver disease (NAFLD) is known as the hepatic manifestation of the metabolic syndrome, and while most patients develop simple steatosis, up to one-third can develop nonalcoholic steatohepatitis (NASH). NASH is a chronic inflammatory condition of the liver that can further progress...
Furkejuvvon:
| Materiálatiipa: | Online |
|---|---|
| Giella: | eaŋgalasgiella |
| Almmustuhtton: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Fáttát: | |
| Liŋkkat: | ONIX_20220224_9783036529790_116 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
| _version_ | 1869528792464097280 |
|---|---|
| collection | Directory of Open Access Books |
| description | Nonalcoholic fatty liver disease (NAFLD) is known as the hepatic manifestation of the metabolic syndrome, and while most patients develop simple steatosis, up to one-third can develop nonalcoholic steatohepatitis (NASH). NASH is a chronic inflammatory condition of the liver that can further progress to fibrosis and cirrhosis, which may eventually lead to liver failure and death. While we have increased our mechanistic knowledge regarding the pathogenesis of NASH within the last decade, treatment options are still limited and liver biopsies have remained the gold standard for diagnosis. To achieve major clinical breakthroughs for NASH patients, it is not sufficient to use a single animal model, since each model has specific limitations. Furthermore, we should rely more on alternative models such as organ-on-a-chip, which will enable us to explore unknown aspects of disease pathogenesis much faster and serve as clinically relevant surrogates for murine models. Another important direction for the improvement of patient health is to pay more attention to extrahepatic, organ-specific and systemic effects, which are associated with NASH. The articles in this Special Issue include an up-to-date overview of the rapidly developing technologies, novel targets for intervention and insights in the field in NASH. Additionally, these articles describe the major challenges in the field, strategies to overcome them and suggestions for future directions. To improve patient’s outcome, clinicians, as well as scientists with biomedical, nutrition, physics and mathematics backgrounds, should join forces. Although challenges remain, the future of the field seems promising as these novel technologies and developments are expected to lead to progress in NASH. |
| format | Online |
| id | doab-20.500.12854ir-78818 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-788182024-03-27T16:34:44Z NASH and Systemic Complications Shiri-Sverdlov, Ronit Baumgartner, Sabine NAFLD mouse models multifactorial disease translational value non-alcoholic fatty liver disease steatohepatitis NASH cognitive impairment memory dysfunction Alzheimer’s disease neurodegeneration liver stiffness liver steatosis controlled attenuation parameter transient elastography MRI PDFF MR spectroscopy non-alcoholic steatohepatitis (NASH) tunneling nanotubes (TNTs) primary hepatocytes organelle transfer mesenchymal stromal cells aminopyrine microsomal liver function breath test nonalcoholic fatty liver disease nonalcoholic steatohepatitis extracellular vesicles magnesium (Mg2+) obesity insulin resistance (IR) type 2 diabetes mellitus (T2DM) hypertension cardiovascular diseases (CVD) non-alcoholic steatohepatitis intestinal permeability microbiota probiotics physical exercise fecal microbiota transplantation hepatocellular carcinoma pathogenesis extra-hepatic outcome organ-on-a-chip artificial intelligence liver disease GLP-1 agonist SGLT-2 inhibitor type 2 diabetes innate immune system adaptive immune system metabolic syndrome fatty liver leptin n/a thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general Nonalcoholic fatty liver disease (NAFLD) is known as the hepatic manifestation of the metabolic syndrome, and while most patients develop simple steatosis, up to one-third can develop nonalcoholic steatohepatitis (NASH). NASH is a chronic inflammatory condition of the liver that can further progress to fibrosis and cirrhosis, which may eventually lead to liver failure and death. While we have increased our mechanistic knowledge regarding the pathogenesis of NASH within the last decade, treatment options are still limited and liver biopsies have remained the gold standard for diagnosis. To achieve major clinical breakthroughs for NASH patients, it is not sufficient to use a single animal model, since each model has specific limitations. Furthermore, we should rely more on alternative models such as organ-on-a-chip, which will enable us to explore unknown aspects of disease pathogenesis much faster and serve as clinically relevant surrogates for murine models. Another important direction for the improvement of patient health is to pay more attention to extrahepatic, organ-specific and systemic effects, which are associated with NASH. The articles in this Special Issue include an up-to-date overview of the rapidly developing technologies, novel targets for intervention and insights in the field in NASH. Additionally, these articles describe the major challenges in the field, strategies to overcome them and suggestions for future directions. To improve patient’s outcome, clinicians, as well as scientists with biomedical, nutrition, physics and mathematics backgrounds, should join forces. Although challenges remain, the future of the field seems promising as these novel technologies and developments are expected to lead to progress in NASH. 2022-02-24T10:37:34Z 2022-02-24T10:37:34Z 2022 book ONIX_20220224_9783036529790_116 9783036529790 9783036529783 https://directory.doabooks.org/handle/20.500.12854/78818 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/4913 https://mdpi.com/books/pdfview/book/4913 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-2979-0 10.3390/books978-3-0365-2979-0 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036529790 9783036529783 232 Basel open access |
| spellingShingle | NAFLD mouse models multifactorial disease translational value non-alcoholic fatty liver disease steatohepatitis NASH cognitive impairment memory dysfunction Alzheimer’s disease neurodegeneration liver stiffness liver steatosis controlled attenuation parameter transient elastography MRI PDFF MR spectroscopy non-alcoholic steatohepatitis (NASH) tunneling nanotubes (TNTs) primary hepatocytes organelle transfer mesenchymal stromal cells aminopyrine microsomal liver function breath test nonalcoholic fatty liver disease nonalcoholic steatohepatitis extracellular vesicles magnesium (Mg2+) obesity insulin resistance (IR) type 2 diabetes mellitus (T2DM) hypertension cardiovascular diseases (CVD) non-alcoholic steatohepatitis intestinal permeability microbiota probiotics physical exercise fecal microbiota transplantation hepatocellular carcinoma pathogenesis extra-hepatic outcome organ-on-a-chip artificial intelligence liver disease GLP-1 agonist SGLT-2 inhibitor type 2 diabetes innate immune system adaptive immune system metabolic syndrome fatty liver leptin n/a thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general NASH and Systemic Complications |
| title | NASH and Systemic Complications |
| title_full | NASH and Systemic Complications |
| title_fullStr | NASH and Systemic Complications |
| title_full_unstemmed | NASH and Systemic Complications |
| title_short | NASH and Systemic Complications |
| title_sort | nash and systemic complications |
| topic | NAFLD mouse models multifactorial disease translational value non-alcoholic fatty liver disease steatohepatitis NASH cognitive impairment memory dysfunction Alzheimer’s disease neurodegeneration liver stiffness liver steatosis controlled attenuation parameter transient elastography MRI PDFF MR spectroscopy non-alcoholic steatohepatitis (NASH) tunneling nanotubes (TNTs) primary hepatocytes organelle transfer mesenchymal stromal cells aminopyrine microsomal liver function breath test nonalcoholic fatty liver disease nonalcoholic steatohepatitis extracellular vesicles magnesium (Mg2+) obesity insulin resistance (IR) type 2 diabetes mellitus (T2DM) hypertension cardiovascular diseases (CVD) non-alcoholic steatohepatitis intestinal permeability microbiota probiotics physical exercise fecal microbiota transplantation hepatocellular carcinoma pathogenesis extra-hepatic outcome organ-on-a-chip artificial intelligence liver disease GLP-1 agonist SGLT-2 inhibitor type 2 diabetes innate immune system adaptive immune system metabolic syndrome fatty liver leptin n/a thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general |
| topic_facet | NAFLD mouse models multifactorial disease translational value non-alcoholic fatty liver disease steatohepatitis NASH cognitive impairment memory dysfunction Alzheimer’s disease neurodegeneration liver stiffness liver steatosis controlled attenuation parameter transient elastography MRI PDFF MR spectroscopy non-alcoholic steatohepatitis (NASH) tunneling nanotubes (TNTs) primary hepatocytes organelle transfer mesenchymal stromal cells aminopyrine microsomal liver function breath test nonalcoholic fatty liver disease nonalcoholic steatohepatitis extracellular vesicles magnesium (Mg2+) obesity insulin resistance (IR) type 2 diabetes mellitus (T2DM) hypertension cardiovascular diseases (CVD) non-alcoholic steatohepatitis intestinal permeability microbiota probiotics physical exercise fecal microbiota transplantation hepatocellular carcinoma pathogenesis extra-hepatic outcome organ-on-a-chip artificial intelligence liver disease GLP-1 agonist SGLT-2 inhibitor type 2 diabetes innate immune system adaptive immune system metabolic syndrome fatty liver leptin n/a thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general |
| url | ONIX_20220224_9783036529790_116 |